Publications

The European Commission has approved nivolumab (Opdivo) at a flat dosing schedule of either 240 mg over 30 minutes every 2 weeks, or 480 mg infused over 60 minutes every 4 weeks, for the adjuvant treatment of patients with melanoma who have involvement of lymph nodes or metastatic disease who have undergone complete resection.1

NEW YORK – Taiwanese cancer diagnostic firm ACT Genomics said on Monday that it has launched a study in collaboration with the University of California, San Diego Moores Cancer Center that will evaluate gene expression signals associated with the tumor microenvironment that may predict outcome in melanoma patients treated with PD-1 inhibition.

In patients with metastatic melanoma, researchers ascertained if the presence and the characteristics of pretreatment CD8+ tumor-infiltrating T lymphocytes (TILs) could be a complementary prognostic or predictive biomarker.